Polish Atrial Fibrillation (POL-AF) Registry
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 4,000
- 试验地点
- 1
- 主要终点
- Assessment of the frequency of VKAs vs NOACs prescription in AF patients treatment of with OACs.
研究概览
简要总结
Evaluation of clinical characteristics and pharmacotherapy of hospitalized Polish patients with atrial fibrillation (AF).
详细描述
Atrial fibrillation (AF) is a common arrhythmia associated with increased cardiovascular mortality. An important element of management of patients with AF is anticoagulation to prevent thromboembolic events. Non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) are two main drugs groups used in thromboembolic events prevention.
Primary objective of the study is to assess the frequency of VKAs vs NOACs prescription in AF patients treatment of with OACs.
Secondary objective of the study are as follows: assessment of the frequency of appropriate/inappropriate OACs prescription in AF patients and assesment of the number of patients with AF treated with apixaban, dabigatran and rivaroxaban with high thromboembolism risk according to CHA2DS2-VASc score.
The POL-AF Registry is a multicenter prospective analysis of hospital records of patients with AF managed in ten cardiology centers.
Collected data will include demographics, type of AF (valvular and non-valvular, as well as paroxysmal, persistent and permanent), medical history, laboratory tests, echocardiographic parameters and concomitant medications.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with AF hospitalized in a participating center during study period
排除标准
- •hospitalisation for atrial fibrillation ablation
- •death during hospitalization
结局指标
主要结局
Assessment of the frequency of VKAs vs NOACs prescription in AF patients treatment of with OACs.
时间窗: Through the study completion, an average of 2 months.
Compared data will include: frequency of VKAs vs NOACs prescriptions.
次要结局
- Assessment of the frequency of appropriate/inappropriate OACs prescription in AF patients.(Through the study completion, an average of 2 months.)
- Number of patients with AF treated with apixaban, dabigatran and rivaroxaban with high thromboembolism risk according to CHA2DS2-VASc (heart failure, hypertension, age, diabetes mellitus, stroke/TIA/thromboembolism, vascular disease and sex) score.(Through the study completion, an average of 2 months.)
研究者
Iwona Gorczyca
MD, PhD, Principal Investigator
Jan Kochanowski University